Kombinationswirkung von paclitaxel und ionisierender strahlung: Experimentelle daten aus in-vitro- und in-vivo-modellen

Strahlentherapie und Onkologie

Volumn 172, Issue SUPPL. 1, 1996, Pages 1-20

  Rube C ^c   Hampel, G ^c   Schuck, A ^c   Willich, N ^a   Hoffmann, Wolfgang ^b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

^c NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0344946201     PISSN: 01797158     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Chang, A. Y., K. Kim, J. Glick, D. Karp, D. Johnson: Phase II study of paclitaxel, merbarone and piroxantrone in stage IV non small cell lung cancer: the Eastern Cooperative Oncology Group results. J. nat. Cancer Inst. 85 (1993), 388-394.
2. Forastiere, A. A., B. Metch, D. E. Schuller: Randomized comparison of cisplatin plus fluorouracil and carboplatin and fluorouracil versus methotrexate in advanced squamous-cell carcinoma of the head and neck: South West Oncology Group Study. J clin. Oncol. 10 (1992), 1245-1251.
3. Forastiere, A. A., D. Neuberg, S. G. Taylor, R. DeConti, G. Adanns: Phase II evaluation of paclitaxel in advanced head and cancer: an Eastern Cooperativ Oncology Group trial. Proc. Amer. Soc. clin. Oncol. 12 (1993), 277.
4. Gerad, C. R., J. M. Jones: Radiation and paclitaxel effects on synchronized human cervical carcinoma cells. Int. J. Radiat. Oncol. Biol. Phys. 29 (1994), 565-569.
5. Hoffmann, W., M. Bamberg, H. P. Rodemann: Antiproliferative effects of ionizing radiation, all-trans retinoic acid and interferon on cultured human squamous cell carcinomas. Radiat. Oncol. Invest. 2 (1994), 12-19.
6. Hoffmann, W., V. Heinrich, C. Belka, W. Budach, H. Schmidberger, H. Bochtler, H. P. Rodemann, M. Bamber. Paclitaxel in simultaneous radio/chemotherapy of head and neck cancer - preclinical and clinical results. Semin. Oncol. (accepted, in press).
7. Holms, F. A., R. S Walters, R. L. Thierault et al.: Phase II trial of paclitaxel, an active drug in the treatment of metastic breast cancer. J. nat. Cancer Inst 83 (1991), 1797-1805.
8. Jacobs, C. R. Makuch: Efficacy of adjuvant chemotherapy for patients with resectable head and neck cancer: a subset analysis of the head and neck contracts program. J. clin. Oncol. 8 (1990), 838-847.
9. Kuerbitz, S. J., B. S. Plunkett, W. V. Walsh et al.: Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. nat. Acad. Sci. (Wash.) 89 (1992), 7491-7495.
10. Liebmann, J. E., J. A. Cook, J. Fisher, D. Tengue, J. B. Mitchell: Changes of survival curve parameters in human tumour and rodent cells exposed to paclitaxel (Paclitaxel). Int. J. Radiat Oncol. Biol. Phys. 29 (1994), 559-564.
11. McGuire, W. P., E. K. Rowinsky, N. B. Rosenhein, F. G Grumbine, D. S Ettinger, D. K. Armstrong, R. C. Donehower: Paclitaxel: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann. intern. Med 111 (1989), 273-279.
12. Min, B. M., J H. Baek, K H. Shin, C. N. Gujuluva, H. U. Cherrick, N. H. Park: Inactivation of the p53 gene bei either mutation or HPV infection is extremely frequent in human oral squamous cell carcinoma cell lines Europ J. Cancer 30 (1994), 338-345.
13. Murphy, W. K., F. V. Fossella, R. J. Winn, D. U. Shimm, H. E. Heynes, H. M. Gross, E. Davella, J. Leenert: Phase II study of paclitaxel in patients with untreated advanced non small cell lung cancer. J. nat. Cancer Inst. 85 (1993), 384-388
14. Rijn, J., J van den Berg, O. Meijer. Proliferation and clonal survival of human lung cancer cells treated with fractionated irradiation in combination with paclitaxel. Int. J Radiat. Oncol. Biol. Phys. 33 (1995), 635-639.
15. Rodemann, H. P., K. Bayreuther, P. I. Francz, K. Dittmann, U. Albiez: Selective enrichment and biochemical characterization of seven cell types of human skin fibroblasts populations in vitro. Exp. Cell Res. 180 (1989), 84-93.
16. Schiff, P. B., J. Fant, S. B. Horwitz: Promotion of microtubuli assembly in vitro by Paclitaxel. Nature 277 (1979), 665-667.
17. Schiff, P. B., R. Gubit, S. Kashimawo: Interaction with ionizing radiation. In: McGuire, W. P., E. K. Rowinsky (eds.): Paclitaxel in cancer treatment. Marcel Dekker, New York 1995, p. 81-89
18. Schiff, P. B., S. B. Horowitz: Paclitaxel stabilizes microtubles in mouse fibroblast cells. Proc nat. Acad. Sci. (Wash.) 77 (1980), 1561-1565
19. Steren, A., B U. Sevin, J. Perras, R- Angioli, H. Nguyen, L. Guerrce, O. Koechli: Paclitaxel sensitizes human ovarian cancer cells to radiation. Cancer Res. 48 (1993), 252-258.
20. Tishler, R. B., C. R. Geard, E. J. Hall et al.: Paclitaxel sensitizes human astrocytoma cells to radiation. Cancer Res. 52 (1992), 3495-3497.
21. Tsang, N. M., H. Nagasawa, C. Li. J. B. Little: Abrogation of p53 function by transfection of HPV16 E6 gene enhances the resistance of human diploid fibroblasts to ionizing radiation. Oncogene 10 (1995), 2403-2408.
22. Vokes, E. E , P. Mick, E. P. Lester, W. R Panje, R. R. Weichselbaum: Cisplatin and 5-fluorouracil does not yield long-term benefit in locally advanced head and neck cancer: results from a single institution. J. clin. Oncol. 9 (1992), 1376-1384.
23. Vokes, E. E., R. Stupp, D. Haraf et al.: Hydroxyurea with continuous infusion paclitaxel, 5-fluorouracil and concomitant radiotherapy for poor prognosis head and neck cancer. Semin. Oncol. 22, Suppl. 6 (1995), 47-52.
24. Wolf, G. T., W. K. Hong, S. Gross-Fischer: Induction chemotherapy plus radioation compared with surgery plus radiation in patints with advanced larnygeal cancer. The department of Veterans Affairs Laryngeal Cancer Study Group. New Engl. J. Med. 324 (1991), 1685-1690.